30 closest matches · ranked by relevance
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) — 9.574 months
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation — 13.7 months
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)…
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Anticancer Treatment
Primary: Progression Free Survival (PFS) by Investigator Assessment — 10.1; 4.4 Months — p=<0.001
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Tested Positive for EGFR Mutations — 8.1 percentage of participants
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 12.846 Months
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Primary: Median Progression Free Survival (PFS) (Months) — 18.9; 10.2; 17.8; 9.8 Months — p=<0.0001
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
EGFR Exon 19 Deletion Mutation · EGFR NP_005219.2:p.L858R · Lung Non-Squamous Non-Small Cell Carcinoma
Primary: Progression Free Survival (PFS) — 13.5; 17.9 months — p=0.39
Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients With Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 478 Participants
Carcinoma，Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 387.000 days
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 18.2 Percentage of Participants
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Primary: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression — 2.0; 3.9; 2.0; 3.9 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Non-Small Cell Lung Cancer
Primary: Progression Free-survival — 9.4; 5.2 months — p=0.0001
NSCLC
Primary: Disease Control (Defined as Complete or Partial Response, or Disease Stabilisation Lasting at Least 12 Weeks) — 7; 6; 4; 5 Participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival Per RECIST, v. 1.1 (PFS1) — 11.000 months
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment of Afatinib as First-line Therapy in Advanced Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Mutation — 14.4 Months
Non-Small Cell Lung Cancer
Primary: ORR According to RECIST 1.1 by Independent Review — 62.0 % of participants